Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI

In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis. 

Subscribe to Eagle’s Eye View